Rucaparib Could Extend Survival for Uterine Cancer Patients
By Dennis Thompson HealthDay Reporter
FRIDAY, March 22, 2024 -- An already approved cancer drug could be an effective treatment for women with advanced, recurring uterine cancer, a new clinical trial shows.
Rucaparib, which belongs to a class of drugs called PARP inhibitors, extended women’s survival for more than a year and a half, on average, compared to simple surveillance following chemotherapy, researchers report.
“We improved patients’ progression-free survival, meaning time without recurrence or progression, by an average of 19 months,” said lead researcher Dr. Bradley Corr, an oncologist with the University of Colorado Cancer Center.
“Patients on placebo had a progression-free survival of nine months, whereas it was 28 months for those who had received rucaparib,” Corr added in a university news release. “This is very significant for our patients and for their care.”
Rucaparib currently is approved to treat breast, ovarian and prostate cancer, Corr said.
PARP inhibitors work by blocking naturally occurring enzymes that help damaged cells repair themselves. Unfortunately, these enzymes also help cancer cells recover from damage done by chemotherapy.
Uterine cancer, also known as endometrial cancer, affects more than 60,000 women in the United States each year, and is one of the few cancers in which cases are increasing, researchers said in background notes.
Survival for early-stage uterine cancer is high, at more than 80%, but survival rates decrease dramatically in advanced cases, the researchers said.
In the clinical trial, all patients underwent one or two courses of chemotherapy, and then half were randomly assigned to take rucaparib, which comes in pill form.
Currently, the only treatment option for uterine cancer patients following chemotherapy is to watch and wait, in hopes their cancer won’t return, researchers said.
The unfortunate reality is that most late-stage uterine cancers eventually come back after chemo, Corr said.
These results show that rucaparib can extend the time before patients’ cancer returns, Corr said.
Researchers suspect rucaparib works against uterine cancer because it blocks off DNA damage repair pathways.
For their next step, Corr and his team will analyze the tumors and patients, to better identify who most benefitted from treatment with the drug.
The findings were presented this week at the Society of Gynecologic Oncologists annual meeting in San Diego. Such research is typically considered preliminary until published in a peer-reviewed journal.
Sources
- University of Colorado, news release, March 20, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Breast Cancer Survivors Face Higher Odds for Second Cancer
THURSDAY, April 25, 2024 -- People lucky enough to survive a breast cancer may still face heightened risks for other cancers later, a new study shows. The researchers stressed...
Today's Young Adults Are Aging Faster, and That Might Help Spur Cancers
MONDAY, April 8, 2024 -- Younger generations are aging more rapidly, and this could be leading to an increased risk of cancer, a new study says. People born in or after 1965 are...
High-Tech Screening Might Spot More Cancer Patients Who'd Benefit From Immunotherapy
FRIDAY, Dec. 29, 2023 -- More patients could benefit from immunotherapy, a highly effective treatment for some cancers, new research suggests. Revising current testing guidelines...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
